vs

Side-by-side financial comparison of CONSUMER PORTFOLIO SERVICES, INC. (CPSS) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

CONSUMER PORTFOLIO SERVICES, INC. is the larger business by last-quarter revenue ($109.4M vs $75.5M, roughly 1.5× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 3.9%). CONSUMER PORTFOLIO SERVICES, INC. produced more free cash flow last quarter ($288.3M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 9.2%).

Consumer Portfolio Services, Inc. is a U.S. specialty finance firm providing indirect auto loan financing and servicing for consumers with limited or subprime credit. It partners with franchised and independent car dealerships nationwide to originate installment contracts for new and used vehicle purchases.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CPSS vs PBYI — Head-to-Head

Bigger by revenue
CPSS
CPSS
1.5× larger
CPSS
$109.4M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+23.8% gap
PBYI
27.7%
3.9%
CPSS
More free cash flow
CPSS
CPSS
$273.9M more FCF
CPSS
$288.3M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
9.2%
CPSS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPSS
CPSS
PBYI
PBYI
Revenue
$109.4M
$75.5M
Net Profit
$5.0M
Gross Margin
69.3%
Operating Margin
6.6%
22.7%
Net Margin
4.6%
Revenue YoY
3.9%
27.7%
Net Profit YoY
-3.2%
EPS (diluted)
$0.21
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPSS
CPSS
PBYI
PBYI
Q4 25
$109.4M
$75.5M
Q3 25
$108.4M
$54.5M
Q2 25
$109.8M
$52.4M
Q1 25
$106.9M
$46.0M
Q4 24
$105.3M
$59.1M
Q3 24
$100.6M
$80.5M
Q2 24
$95.9M
$47.1M
Q1 24
$91.7M
$43.8M
Net Profit
CPSS
CPSS
PBYI
PBYI
Q4 25
$5.0M
Q3 25
$4.9M
$8.8M
Q2 25
$4.8M
$5.9M
Q1 25
$4.7M
$3.0M
Q4 24
$5.1M
Q3 24
$4.8M
$20.3M
Q2 24
$4.7M
$-4.5M
Q1 24
$4.6M
$-4.8M
Gross Margin
CPSS
CPSS
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
CPSS
CPSS
PBYI
PBYI
Q4 25
6.6%
22.7%
Q3 25
6.5%
17.6%
Q2 25
6.3%
12.7%
Q1 25
6.4%
8.7%
Q4 24
7.0%
22.6%
Q3 24
6.8%
27.4%
Q2 24
7.0%
-4.6%
Q1 24
7.1%
-5.3%
Net Margin
CPSS
CPSS
PBYI
PBYI
Q4 25
4.6%
Q3 25
4.5%
16.2%
Q2 25
4.4%
11.2%
Q1 25
4.4%
6.5%
Q4 24
4.9%
Q3 24
4.8%
25.2%
Q2 24
4.9%
-9.6%
Q1 24
5.0%
-11.0%
EPS (diluted)
CPSS
CPSS
PBYI
PBYI
Q4 25
$0.21
$0.26
Q3 25
$0.20
$0.17
Q2 25
$0.20
$0.12
Q1 25
$0.19
$0.06
Q4 24
$0.21
$0.40
Q3 24
$0.20
$0.41
Q2 24
$0.19
$-0.09
Q1 24
$0.19
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPSS
CPSS
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$6.3M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$309.5M
$130.3M
Total Assets
$3.9B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPSS
CPSS
PBYI
PBYI
Q4 25
$6.3M
$97.5M
Q3 25
$9.4M
$94.4M
Q2 25
$15.8M
$96.0M
Q1 25
$29.8M
$93.2M
Q4 24
$11.7M
$101.0M
Q3 24
$8.1M
$96.7M
Q2 24
$9.8M
$96.8M
Q1 24
$13.2M
$107.2M
Total Debt
CPSS
CPSS
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
CPSS
CPSS
PBYI
PBYI
Q4 25
$309.5M
$130.3M
Q3 25
$307.6M
$115.3M
Q2 25
$303.1M
$104.7M
Q1 25
$298.4M
$97.1M
Q4 24
$292.8M
$92.1M
Q3 24
$285.1M
$71.1M
Q2 24
$280.3M
$48.5M
Q1 24
$279.1M
$51.0M
Total Assets
CPSS
CPSS
PBYI
PBYI
Q4 25
$3.9B
$216.3M
Q3 25
$3.8B
$202.9M
Q2 25
$3.8B
$194.9M
Q1 25
$3.7B
$196.2M
Q4 24
$3.5B
$213.3M
Q3 24
$3.5B
$220.7M
Q2 24
$3.3B
$205.0M
Q1 24
$3.0B
$214.1M
Debt / Equity
CPSS
CPSS
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPSS
CPSS
PBYI
PBYI
Operating Cash FlowLast quarter
$289.0M
$14.4M
Free Cash FlowOCF − Capex
$288.3M
$14.4M
FCF MarginFCF / Revenue
263.5%
19.1%
Capex IntensityCapex / Revenue
0.6%
0.0%
Cash ConversionOCF / Net Profit
58.02×
TTM Free Cash FlowTrailing 4 quarters
$500.9M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPSS
CPSS
PBYI
PBYI
Q4 25
$289.0M
$14.4M
Q3 25
$84.9M
$9.7M
Q2 25
$54.5M
$14.1M
Q1 25
$73.9M
$3.6M
Q4 24
$233.8M
$15.6M
Q3 24
$69.8M
$11.0M
Q2 24
$43.3M
$1.0M
Q1 24
$52.7M
$11.2M
Free Cash Flow
CPSS
CPSS
PBYI
PBYI
Q4 25
$288.3M
$14.4M
Q3 25
$84.9M
$9.7M
Q2 25
$54.3M
$14.1M
Q1 25
$73.4M
$3.6M
Q4 24
$233.3M
$15.6M
Q3 24
$69.7M
$11.0M
Q2 24
$43.1M
$1.0M
Q1 24
$52.6M
FCF Margin
CPSS
CPSS
PBYI
PBYI
Q4 25
263.5%
19.1%
Q3 25
78.3%
17.7%
Q2 25
49.5%
26.8%
Q1 25
68.7%
7.7%
Q4 24
221.6%
26.4%
Q3 24
69.3%
13.7%
Q2 24
45.0%
2.1%
Q1 24
57.3%
Capex Intensity
CPSS
CPSS
PBYI
PBYI
Q4 25
0.6%
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.1%
0.0%
Q1 25
0.4%
0.1%
Q4 24
0.4%
0.0%
Q3 24
0.1%
0.0%
Q2 24
0.2%
0.0%
Q1 24
0.1%
0.0%
Cash Conversion
CPSS
CPSS
PBYI
PBYI
Q4 25
58.02×
Q3 25
17.50×
1.10×
Q2 25
11.35×
2.41×
Q1 25
15.74×
1.21×
Q4 24
45.43×
Q3 24
14.55×
0.54×
Q2 24
9.27×
Q1 24
11.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons